Literature DB >> 20944936

[Intravitreal injection of ketorolac tromethamine in patients with diabetic macular edema refractory to retinal photocoagulation].

Andreia do Ceu Afonso Reis1, Raul Nunes Galvarro Vianna, Ricardo Siqueira Mendes dos Reis, Gilberto Perez Cardoso.   

Abstract

PURPOSE: To evaluate the effect of a single dose of intravitreous injection of ketorolac tromethamine (500 µg/0.1 ml) in patients with diabetic macular edema refractory to retinal photocoagulation.
METHODS: Prospective study. Twenty patients with bilateral diabetic macular edema and ETDRS best-corrected visual acuity between 20/50 and 20/200 were selected. Patients who had other ocular diseases or previous eye surgery were excluded. Preservative-free ketorolac tromethamine was injected intravitreally (500 µg in 0.1 ml) in 20 eyes; fellow eyes served as controls. Ophthalmic examinations included ETDRS best-corrected visual acuity, measurement of intraocular pressure and optical coherence tomography. The examinations were performed preoperatively, 1 week and 1 month postoperatively.
RESULTS: A statistically significant increase in visual acuity over time in the treated eye compared with the fellow eye was noted (p=0.039). There were no statistically significant differences in the assessment of intraocular pressure (p=0.99), foveal thickness (p=0.86) and macular volume (p=0.23) during the period.
CONCLUSION: Patients with diabetic macular edema refractory to photocoagulation showed improvement in visual acuity over a one month period with a statistically significant difference when compared with the control eye. There were no statistically significant differences in intraocular pressure, foveolar thickness and macular volume between the treated and control eyes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20944936     DOI: 10.1590/s0004-27492010000400007

Source DB:  PubMed          Journal:  Arq Bras Oftalmol        ISSN: 0004-2749            Impact factor:   0.872


  7 in total

1.  Intravitreal diclofenac versus intravitreal bevacizumab in naive diabetic macular edema: a randomized double-masked clinical trial.

Authors:  Masoud Soheilian; Saeed Karimi; Alireza Ramezani; Talieh Montahai; Mehdi Yaseri; Roham Soheilian; Gholam A Peyman
Journal:  Int Ophthalmol       Date:  2014-07-19       Impact factor: 2.031

2.  Intravitreal Diclofenac plus Bevacizumab versus Bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial.

Authors:  Heshmatollah Ghanbari; Farzan Kianersi; Seyed Ali Sonbolestan; Mohammad-Ali Abtahi; Mojataba Akbari; Zahra-Alsadat Abtahi; Seyed-Hossein Abtahi
Journal:  Int Ophthalmol       Date:  2016-09-13       Impact factor: 2.031

3.  Pharmacokinetics and efficacy of intraocular flurbiprofen.

Authors:  S Blazaki; C Tsika; M Tzatzarakis; E Naoumidi; A Tsatsakis; C Tsatsanis; Miltiadis K Tsilimbaris
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-09-29       Impact factor: 3.117

4.  Intravitreal ketorolac for the treatment of chronic cystoid macular edema after cataract surgery.

Authors:  Miltiadis K Tsilimbaris; Chrysanthi Tsika; George D Kymionis
Journal:  Ther Clin Risk Manag       Date:  2016-02-12       Impact factor: 2.423

5.  Nonsteroidal anti-inflammatory drugs for retinal disease.

Authors:  Scott D Schoenberger; Stephen J Kim
Journal:  Int J Inflam       Date:  2013-01-14

Review 6.  Topical nonsteroidal anti-inflammatory drugs for macular edema.

Authors:  Andrea Russo; Ciro Costagliola; Luisa Delcassi; Francesco Parmeggiani; Mario R Romano; Roberto Dell'Omo; Francesco Semeraro
Journal:  Mediators Inflamm       Date:  2013-10-21       Impact factor: 4.711

7.  Comparison of Intravitreal Bevacizumab and Intravitreal Diclofenac in the Treatment of Diabetic Macular Edema: a 6-month Follow-up.

Authors:  Hooshang Faghihi; Hanif Yahyapour; Raziyeh Mahmoudzadeh; Shahin Faghihi
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2017
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.